Taking an ethical and responsible approach that is in the best interest of our patients underpins our daily activities, and is core to how we approach our business. It always has been, and remains an important priority for us.
One of the best examples of this can be seen in our efforts to improve access to our treatments. Particularly with rare disease therapies, this is a very complex and challenging area, but one that we recognize is critically important to us, to patients, and to physicians around the world. You can read more about these programs, including our work with Direct Relief, Project HOPE and AmeriCares, in this Annual Review. We were pleased to be recognized in 2014 as a constituent of the 100 Most Sustainable Corporations in the World and the FTSE4Good Index. In addition, we received accolades from Newsweek as the 2nd “greenest” company in the world, and Transparency International identified Shire as one of the top 25 UK companies for transparency in corporate reporting.
We are proud of the progress we are making, but are not complacent. We will continue to strive towards greater transparency of our policies, goals and progress towards those goals. We will continue to work with governments, policymakers and payors to improve access to treatments in both developed and developing countries.
And we will continue to invest in developing and marketing new treatments where the need is great and our skills and experience can help most.
Our approach to responsibility serves our patients and creates enduring value for our stakeholders.
Learn more about Shire’s policies and procedures on important issues.